Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
CARLSBAD, Calif. - Palisade Bio, Inc. (NASDAQ:PALI), a clinical-stage biopharmaceutical company with a current market capitalization of $160 million, has appointed Sharon Skare, PhD(c) as Vice President, Global Head of Clinical Operations, the company announced Tuesday. The appointment comes as PALI shares have shown strong momentum, gaining over 124% in the past six months, according to InvestingPro data.
Skare brings over 24 years of leadership experience in global clinical development across autoimmune, metabolic, gastrointestinal, and fibrotic diseases. She previously served as Vice President and Global Head of Clinical Operations at Abivax, overseeing global Phase 3 and Phase 2 programs in ulcerative colitis and Crohn’s disease. Her appointment is crucial as InvestingPro analysis indicates analysts do not expect profitability this year, with the company’s EBITDA currently at -$12.12 million.
"Her extensive experience leading global clinical operations in IBD and her proven success guiding programs through pivotal phases and inspections will be invaluable as we advance PALI-2108 into our planned Phase 2 studies," said Dr. Mitchell Jones, Chief Medical Officer of Palisade Bio.
Prior to Abivax, Skare held senior leadership positions at Pfizer and Arena Pharmaceuticals, where she led the global clinical operations program for Etrasimod, now approved as Velsipity.
Palisade Bio is currently developing PALI-2108, an orally administered prodrug engineered for local delivery of phosphodiesterase-4 inhibition to the terminal ileum and colon. The company recently completed a Phase 1a/1b study for ulcerative colitis and is conducting a Phase 1b study for fibrostenotic Crohn’s disease.
The company plans to submit Phase 2 Investigational New Drug applications to the U.S. Food and Drug Administration in the first half of 2026, according to the press release statement. Investors tracking PALI’s progress can access additional insights through InvestingPro, which offers 11 more exclusive ProTips and detailed financial metrics to evaluate the company’s potential ahead of its next earnings report on November 11, 2025.
In other recent news, Palisade Bio, Inc. announced the termination of its Phantom Unit Plan, ceasing all unvested awards for key executives without consideration. Shareholders of Palisade Bio also approved director elections and a reverse stock split option during the company’s annual meeting. In clinical developments, Palisade Bio has begun dosing patients in a Phase 1b study of PALI-2108 for fibrostenotic Crohn’s disease, with initial data expected in early 2026. The company further reported regaining compliance with Nasdaq’s minimum bid price requirement, resolving an issue that had persisted since April. Additionally, Palisade Bio received a Canadian patent for its lead drug candidate, PALI-2108, securing protection until 2041. These recent developments highlight the company’s ongoing efforts in clinical research and corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.